Migraine Drugs Market is expected to grow to USD 7.6 billion in 2034

• The migraine drugs market was estimated to be worth USD 4.9 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2034, reaching USD 7.6 billion. A variety of patient-specific therapy options are provided by migraine medications. The market is increasing and sustainable since it is in line with the healthcare industry.
• A common and serious neurological condition, migraines are characterized by strong, recurrent headaches that are frequently accompanied by light and sound sensitivity, nausea, and vomiting.
• There are four phases that migraine symptoms can go through, affecting both adults and children: prodrome, aura, attack, and post-drome. Both preventive/prophylactic and acute abortive medications are used in the therapy of migraines.

?

Request For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/migraine-drugs-market

?

GROWTH DRIVERS

• The market is largely driven by the increasing prevalence of migraines, which raises demand for efficient treatments. A JAMA Network report states that overall, the incidence of migraines rose by 34% in men and 56% in women. Women in the 20–29 age group saw the largest increase, going from 600 to 1,000 new cases annually per 100,000 women.
• The NCBI reports that there were an estimated 1.1 billion migraine cases in 2019 and that the prevalence of migraines grew globally by 1.7% between 1990 and 2019. Males and those between the ages of 10 and 14 showed the fastest growth in incidence, whereas females and those between the ages of 20 and 24 had the highest prevalence and DALYs.
• The WHO and Becker report that the expense of healthcare increased to a record high of 10.7% in 2023 from 7.4% in 2022. Globally, the insurer-reported cost trend is expected to average 9.9% in 2024, with some regions experiencing a more significant increase.
• The substantial growth in government health spending across all national income levels is responsible for the surge in health spending to a record high of USD 9 trillion, or over 11% of the world's gross domestic product.

MARKET SEGMENTATION:

·?????????By Type- Acute/Abortive Treatment (Analgesic, Ergotamine, Triptans), Preventive/P Treatment (Beta Blockers, Anti-serotonergic drugs, anti-depressants, anticonvulsants, calcium channel blockers)

·?????????By Route of Administration- Oral, Injectable (Pre-filled Syringes, Vial)

·?????????By Distribution Channel- hospital pharmacies, retail pharmacies and online pharmacies

·?????????By Region-?North America, Europe, Asia Pacific, The Middle East and Africa, South America

Global Key Players:

·?????????Novartis AG

·?????????AstraZeneca

·?????????Amgen Inc.

·?????????Abbvie

·?????????Glaxo SmithKline plc

·?????????Eli Lilly and Compnany

·?????????Abbott Laboratories

·?????????Teva Pharmaceuticals Industries

·?????????Pfizer

·?????????Merck & Co. Inc

·?????????Bausch Health Companies

·?????????Janssen Pharmaceutical Company

·?????????Biohaven Pharmaceutical Holding Company

·?????????Endo Pharmaceutical

·?????????Other Players

For More Information about this Report @ https://www.xresearch.biz/shop/migraine-drugs-market

??????????????????

Contact:???????????????????????????????????????????

Company Name:? xResearch

Contact Person:? James Lin

Email:? [email protected]

Phone:?+1 718-619-8140